Melinta Therapeutics Inc (MLNTQ)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

44 WHIPPANY ROAD MORRISTOWN, NJ 07963

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics for the treatment of infectious diseases. The company provides Solithromycin, an oral and intravenous fluoroketolide for the treatment of community acquired bacterial pneumonia; and Taksta, an oral therapy for the treatment of prosthetic joint, and acute bacterial skin and skin structure infections.

Data as of 2019-12-02 20:39:10 -0500
Market Cap22.139 Million Shares Outstanding13.751 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-25.018
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low11.7 / 1.03 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from MLNTQ instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding MLNTQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MLNTQ BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LOCOCO RYAN CHIEF OPERATING OFFICER

  • Officer
0 2019-10-17 0

BLUM SUSAN VP OF FINANCE & CAO

  • Officer
0 2019-10-17 0

SANFILIPPO JENNIFER A INTERIM CHIEF EXECUTIVE OFFICE

  • Officer
  • Director
600 2019-09-05 0

JOHNSON JOHN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
37,400 2019-06-27 0

GILL DAVID N

  • Director
0 2019-06-11 0

ZACCARDELLI DAVID

  • Director
0 2019-06-11 0

GALEOTA JAMES JR

  • Director
0 2019-06-11 0

KOESTLER THOMAS P

  • Director
0 2019-06-11 0

FERRO KEVIN

  • Director
  • 10% Owner
0 2019-06-11 0

DOWNEY BRUCE

  • Director
0 2019-06-11 0

CAMMARATA SUE CHIEF MEDICAL OFFICER

  • Officer
0 2019-05-16 0

MILLIGAN PETER J CHIEF FINANCIAL OFFICER

  • Officer
0 2019-05-16 0

VATERA HEALTHCARE PARTNERS LLC

VATERA CAPITAL MANAGEMENT LLC

FERRO KEVIN

  • Director
  • 10% Owner
0 2019-02-22 0

VATERA CAPITAL MANAGEMENT LLC

  • Director
  • 10% Owner
16,607,959 2019-01-02 0

KONG GARHENG

  • Director
0 2018-06-12 0

WECHSLER DANIEL MARK SEE REMARKS

  • Officer
  • Director
0 2018-06-12 0

GONZALO CECILIA

  • Director
0 2018-06-12 0

ESTREM PAUL CHIEF FINANCIAL OFFICER

  • Officer
0 2018-06-12 0

DUFFY ERIN CHIEF SCIENTIFIC OFFICER

  • Officer
0 2018-06-12 0

VATERA HEALTHCARE PARTNERS LLC

VATERA HOLDINGS LLC

FERRO KEVIN

  • Director
  • 10% Owner
32,615,196 2018-05-29 0

MEDICINES CO /DE

  • 10% Owner
3,313,702 2018-01-05 0

TEMPERATO JOHN CHIEF COMMERCIAL OFFICER

  • Officer
0 2017-11-03 0

GOLDSTEIN DOV A MD

  • Director
95 2017-03-07 0

HAHN MARK W EVP AND CFO

  • Officer
0 2017-02-23 0

MOORE DAVID CHIEF COMMERCIAL OFFICER

  • Officer
1,500 2017-02-23 0

OLDACH DAVID W. CHIEF MEDICAL OFFICER

  • Officer
1,100 2017-02-23 0

BLUTH JOHN D EVP OF IR AND CORP COMM

  • Officer
0 2017-02-23 0

KENT RICHARD S

  • Director
15,392 2017-01-03 0

DOUGHERTY MICHAEL R

  • Director
2,000 2017-01-03 0

NEFF P SHERRILL

  • Director
2,529,642 2016-10-05 0

FERNANDES PRABHAVATHI PRESIDENT AND CEO

  • Officer
  • Director
247,678 2016-01-01 0

INTERSOUTH ASSOCIATES VI, LLC

INTERSOUTH ASSOCIATES VII, LLC

INTERSOUTH PARTNERS VI LP

INTERSOUTH PARTNERS VII L P

MUMMA MITCH

DOUGHERTY DENNIS

  • 10% Owner
No longer subject to file 2015-08-06 0

QUAKER BIOVENTURES II LP

QUAKER BIOVENTURES CAPITAL II, L.P.

  • 10% Owner
3,527,154 2013-06-19 0

MORRIS I WISTAR III

  • 10% Owner
2,233,001 2012-08-17 0

AISLING CAPITAL II LP

AISLING CAPITAL PARTNERS LLC

AISLING CAPITAL PARTNERS, LP

SCHIFF ANDREW N

PURCELL DENNIS J

ELMS STEVE

  • 10% Owner
3,293,060 2012-02-07 0

AISLING CAPITAL II LP

AISLING CAPITAL PARTNERS LLC

AISLING CAPITAL PARTNERS, LP

  • 10% Owner
2,079,397 2012-02-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments